Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim

Last Updated: February 7, 2023

Details for Patent: 9,926,559

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Which drugs does patent 9,926,559 protect, and when does it expire?

Patent 9,926,559 protects SPINRAZA and is included in one NDA.

This patent has two patent family members in two countries.

Summary for Patent: 9,926,559
Title:Compositions and methods for modulation of SMN2 splicing in a subject
Abstract: Disclosed herein are compounds, compositions and methods for modulating splicing of SMN2 mRNA in a subject. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders, including spinal muscular atrophy.
Inventor(s): Bennett; C. Frank (Carlsbad, CA), Hung; Gene (San Diego, CA), Rigo; Frank (Carlsbad, CA)
Assignee: Biogen MA Inc. (Cambridge, MA)
Application Number:14/760,171
Patent Claim Types:
see list of patent claims

Drugs Protected by US Patent 9,926,559

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Biogen Idec SPINRAZA nusinersen sodium SOLUTION;INTRATHECAL 209531-001 Dec 23, 2016 RX Yes Yes See Plans and Pricing See Plans and Pricing TREATMENT OF SPINAL MUSCULAR ATROPHY See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,926,559

PCT Information
PCT FiledJanuary 09, 2014PCT Application Number:PCT/US2014/010930
PCT Publication Date:July 17, 2014PCT Publication Number: WO2014/110291

International Family Members for US Patent 9,926,559

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 2943225 See Plans and Pricing
World Intellectual Property Organization (WIPO) 2014110291 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.